Towards Healthcare
Immuno-Oncology Drugs Market Grows at 16.34% CAGR from 2025

Immuno-Oncology Drugs Market Growth Fueled by New Partnerships - BMS-BioNTech and AbbVie-Xilio Leading Innovation in 2025

According to market projections, the immuno-oncology drugs sector is expected to grow from USD 94 billion in 2024 to USD 421.27 billion by 2034, reflecting a CAGR of 16.34%. Across the globe, a rising number of cancer patients is associated with the geriatric population, lifestyle choices (smoking, diet), and environmental factors are driving the growth of the market, although North America dominated the market in 2024, by escalated cancer instances which are demanding for robust treatment, efficient IO therapies. 

Content

  • Insight Code: 5863
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The immune-oncology drugs market is projected to reach USD 421.27 billion by 2034, growing at a CAGR of 16.34% from 2024 to 2034.

North America is currently leading the immune-oncology drugs market due to rising cases of cancer and demand for personalized treatment.

The immune-oncology drugs market includes four segments such as by disease type, by treatment type, by distribution channel, and by region.

Some of the key players include Coloplast Corp (Denmark), Bristol Myers Squibb Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (U.S.), etc.

Some of the trends in the market include growing research and development and growing collaboration among key players.

Immune-oncology (IO) is also known as immunotherapies to target the bodys immune system to fight against cancer. The immune system includes a network of cells, organs, and molecules that protect the body from deleterious substances, including cancer cells.

Examples of immuno-oncology drugs include immune checkpoint inhibitors such as pembrolizumab and nivolumab, as well as CAR T-cell therapies.

The future outlook for the global immuno-oncology drugs market in the coming years is ongoing R&D, the increasing cases of cancer, and growing awareness about IO therapies.

US FDA.GOV, NIH.GOV, NCI.GOV, MEDLINEPLUS.GOV, ACTREC.GOV
Any Questions